Business Information
The group's principal activity is to discover and develop therapeutics and diagnostics using synthetic dna. The group's activities are based on two technology platforms: immunomodulatory oligonucleotide (imo) technology that uses synthetic dna to modulate responses of the immune system. The imo compounds designed and developed by the group provide therapeutic benefits in the areas of cancer, allergic asthma and other allergies, infectious diseases and in combinations with vaccines and antibody therapies. The antisense technology uses synthetic dna to inhibit the production of disease-associated proteins at the cellular level. Antisense drug development technology involves the design and synthesis of synthetic dna to bind and inhibit the activity of messenger rna which codes for the production of disease-associated proteins. The trademarks of the group are hybridon (R), gem (R), amplivaxtm, cprtm, cyclicontm, imotm, imoxinetm, ypgtm, and yprtm.
|
|
Name |
Title
|
Email
|
| James Wyngaarden | Chmn. | N/A | | Youssef Zein | Vice Chmn. | N/A | | Sudhir Agrawal | Dir., CEO, Chief Scientific Officer | N/A | | Robert Andersen | CFO, VP - Operations, Treasurer, Sec. | N/A | | Timothy Sullivan | VP - Development Programs | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 2,421 | (16,525) | | 2005 | 2,467 | (13,706) | | 2004 | 943 | (12,735)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
